{"disease":{"id":"infections-meningococcal","name":"infections meningococcal"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04502693","title":"Effectiveness of GlaxoSmithKline Biologicals S.A's Meningococcal Group B and Combined ABCWY Vaccines in Healthy Adolescents and Young Adults","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":3657,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT01144663","title":"Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Co-administered With Pneumococcal and DTPa-HBV-IPV/Hib Vaccines","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":2095,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00614614","title":"Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1558,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00514904","title":"Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 2-10 Year Old Subjects","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1504,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT04886154","title":"A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":1440,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00453986","title":"Lot Consistency, Immuno, Safety of Meningococcal Vaccine GSK134612 Given With Fluarix™ to 18-55 Year-Old Adults","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1352,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT01755689","title":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine With or Without Co-administration of Cervarix and Boostrix in Female Adolescents and Young Adults","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1300,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT03621670","title":"Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1196,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT01154088","title":"Immunogenicity and Safety of Meningococcal Vaccine GSK 134612 Versus Mencevax™ ACWY in Healthy 18-25 Year Olds","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1170,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT02212457","title":"Trial to Assess Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":1063,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00464815","title":"Non-Inferiority of Meningococcal Vaccine GSK134612 Versus Mencevax™ in 11-17 Year-Old Subjects","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1025,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT01165242","title":"Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":1013,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00474266","title":"Safety & Immunogenicity Study of Meningococcal Vaccine GSK134612 Given With Priorix-Tetra™ to 12-23 Month-Old Children","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1000,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT01808365","title":"N. Meningitidis Carriage Study","phase":"","overall_status":"COMPLETED","enrollment_count":1000,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT03652610","title":"A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adults 18 to 40 Years of Age","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":996,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT04318548","title":"Study to Assess the Safety and Immunogenicity of GSK Meningococcal Group B Vaccine When Administered Concomitantly With GSK Meningococcal MenACWY Conjugate Vaccine in Healthy Subjects of 16-18 Years of Age","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":945,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00454909","title":"Immunogenicity and Safety of Meningococcal Vaccine GSK134612 vs. Menactra® in Healthy Adolescent/Adults Aged 10-25 Years.","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":873,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT01939158","title":"Immunogenicity and Safety Study of 1 and 2 Doses of GlaxoSmithKline (GSK) Biologicals' Meningococcal Vaccine MenACWY-TT (GSK134612) in Toddlers, Persistence up to 5 Years After Vaccination and Co-administration With Pfizer's Prevenar 13™Vaccine","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":803,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT00508261","title":"Co-Administration of Meningococcal Vaccine GSK134612 With Infanrix Hexa™ Versus Individual Administration of Each Vaccine","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":793,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT02106390","title":"Safety and Immunogenicity of GlaxoSmithKline Biologicals Meningococcal Group B Vaccine When Administered Concomitantly With GlaxoSmithKline Biologicals MenACWY Conjugate Vaccine to Healthy Infants","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":750,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT05082285","title":"A Study on the Safety, Tolerability and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Infants","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":724,"lead_sponsor_name":"GlaxoSmithKline","has_results":false},{"nct_id":"NCT01682876","title":"Immunogenicity, Safety and 1 Year Persistence of Antibodies After Either One or Two Doses of Meningococcal ACWY Conjugate Vaccine in Healthy Children 2 Through 10 Years of Age.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":715,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT02986854","title":"Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":704,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT01767376","title":"Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Meningococcal Conjugate Vaccine (GSK134612) When Co-administered With Boostrix® in Subjects Between 11 and 25 Years of Age","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":692,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00427908","title":"Study in Children to Evaluate Non-Inferiority and Persistence up to 5 Years of GSK Bio Meningococcal Vaccine 134612","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":613,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00465816","title":"Primary Study to Demonstrate Non-inferiority and Immunogenicity of GSK Biologicals' Meningococcal Vaccine 134612","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":611,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT02946385","title":"Study to Assess the Immunological Long-term Persistence of Antibodies (Abs) 2 Years After GlaxoSmithKline (GSK) Meningococcal ABCWY Vaccination in the V102_15 (NCT02212457) and Response to a Booster in Adolescents","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":604,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT02446743","title":"Combined Study - Phase 3b MenB Long Term Persistence in Adolescents","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":531,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00356369","title":"Study in Adolescents/Adults to Evaluate Non-inferiority&Persistence up to 5 Years of GSK Bio MenACWY Conjugate Vaccine","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":500,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00196976","title":"Safety & Immunogenicity of 1 Dose of GSK134612 in Children 12-14 Months and 3-5 Years Old","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":461,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00674583","title":"Comparison of GSK Biologicals' Meningococcal Vaccine (GSK134612) and Licensed MenC-CRM197 Vaccine in Healthy Children","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":414,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT01235975","title":"Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine Given as One Dose to Healthy Subjects Above 56 Years","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":400,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00718666","title":"The Long-term Antibody Persistence of GSK Biologicals' Meningococcal Vaccine GSK134612 in Healthy Toddlers","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":387,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00471081","title":"Immunogenicity and Safety of Meningococcal Vaccine GSK134612 Given as 1 or 2 Doses to Healthy 9-12 Months Old Toddlers.","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":385,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00758264","title":"Co-administration of Meningococcal Vaccine GSK134612 and Pneumococcal Vaccine GSK1024850A vs Individual Administration","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":363,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00955682","title":"Study to Evaluate Persistence of Antibodies After Vaccination With Meningococcal Vaccine GSK134612","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":342,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT01732627","title":"Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":301,"lead_sponsor_name":"Sanofi Pasteur, a Sanofi Company","has_results":true},{"nct_id":"NCT00291343","title":"Immune Response & Safety of GSK Biologicals' Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":296,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT01266993","title":"Persistence and Booster Study of GSK Biologicals' Meningococcal Vaccine (GSK134612) in Healthy Children","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":271,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00661557","title":"Comparison of GSK134612 in Subjects Previously Vaccinated Against Meningococcal Disease Versus Non-vaccinated Subjects","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":271,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00290329","title":"Safety of Purified Meningococcal Vaccine With Serogroups ACWY, in 3,000 Filipino Subjects Aged > 2 Years","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":249,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT06834100","title":"Assessment of Immunogenicity, Reactogenicity and Safety of the Drug GNG-DE in Comparison With the Reference Drug","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"NPO Petrovax","has_results":false},{"nct_id":"NCT02173704","title":"Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan.","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":225,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT00317109","title":"Study to Asses DTPw-HBV/Hib at 15-18 Months (m) and Mencevax™ ACW at 24 to 30 m in Primed Subjects","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":168,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT01777308","title":"Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' MenACWY-TT Vaccine Administered 6 Years Post-MenC Primary Vaccination in Healthy Subjects Who Were 12-18 Months at Primary Vaccination","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":156,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT02287688","title":"Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Infant Study","phase":"","overall_status":"COMPLETED","enrollment_count":144,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT02451514","title":"A Study to Evaluate 4-year Antibody Persistence and Booster Response Following MenABCWY Vaccination in Healthy Adolescents and Young Adults Who Previously Participated in Studies V102_02 (NCT01210885) and V102_02E1 (NCT01367158)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":129,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT02446691","title":"Evaluation of Antibody Persistence Following 4 MenACWY Vaccinations","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":128,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT02223637","title":"Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry","phase":"","overall_status":"COMPLETED","enrollment_count":93,"lead_sponsor_name":"GlaxoSmithKline","has_results":true},{"nct_id":"NCT01641042","title":"Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for Meningococcal Disease Versus Healthy Subjects","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":86,"lead_sponsor_name":"GlaxoSmithKline","has_results":true}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}